Compare BridgeBio Pharma Inc (BBIO) vs Microsoft (MSFT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Microsoft — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Microsoft trades at $501.63 (market cap $3.76T). The key difference: Microsoft is far larger — about 226.4× BridgeBio Pharma Inc's market cap, and Microsoft pays a 0.72% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | MSFT | |
|---|---|---|
Market Cap | $16.61B | $3.76T |
Sector | Health | Technology |
52-Week High | $90.17 | $542.07 |
52-Week Low | $47.29 | $352.83 |
Enterprise Value | $18.16B | $3.74T |
Volume | — | 36,654,621 |
Dividend Yield | — | 0.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
Microsoft (MSFT) trades at $503.81, up 0.76% on the day, with a bullish technical signal and strong fundamentals. The stock shows robust revenue growth, with Q2 2026 EPS beating estimates at $4.74 versus $4.24 expected, and a net income margin of 40.31%. Recent news highlights AI leadership and Azure momentum, though RSI levels indicate overbought conditions near resistance at $507.
Outlook remains positive with an 80.49% analyst buy rating and consensus price target of $553.70, offering potential upside. Risks include high capital expenditures and competitive pressures in AI. The stock's valuation at a P/E of 28.19 reflects premium pricing, but earnings growth and dividend stability support long-term investor appeal.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Microsoft
Microsoft Corporation develops, manufactures, licenses, sells, and supports software products. The Company offers operating system software, server application software, business and consumer applications software, software development tools, and Internet and intranet software. Microsoft also develops video game consoles and digital music entertainment devices.
Read more on MSFT →
